Sign in
Taking people in United StatesPhase 2

Donor-derived natural killer cells for neuroblastoma that has returned or not responded

Tests donor-derived natural killer cells in people with relapsed or hard-to-treat neuroblastoma.

Key facts

Who runs it
Children's Hospital Medical Center, Cincinnati
Where
Cincinnati, United StatesSee the site
Trial code
Registry title
Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Starts
Dec 2026
Expected to end
Jun 2031
Type of study
Interventional
Treatments tested
  • CIML-NK Cells
Record updated
24 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 1 to 39 with high-risk neuroblastoma that has come back or has not responded to treatment, and who have a haploidentical related donor.

Age
1 to 39 years
Sex
All sexes can join.
Disease stage
High-risk neuroblastoma (confirmed by biopsy) that has relapsed, progressed, or not responded to induction chemotherapy. The disease must be measurable or visible on scans or in bone marrow within four weeks of enrolment.
Earlier treatment
Must have had frontline or induction therapy. Failure to reach a complete response after at least four cycles of multidrug induction chemotherapy counts as refractory disease.
Biomarker or test result
The tumour must take up MIBG, FDG or 68Ga-DOTATATE on scans, or there must be cancer cells in the bone marrow.

Main reasons for not taking part

  • Active infection that is not under control, or a live vaccine in the last 30 days
  • Serious heart, lung, kidney or liver problems as defined in the record
  • Taking more than 0.5 mg/kg prednisone equivalent daily
  • Another investigational treatment within 30 days
  • Known allergy to IL-2 injections, or pregnant or breastfeeding

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age 1-39 years at the time of study enrollment
  • With diagnosis of neuroblastoma with histologic verification
  • Classified as high-risk neuroblastoma as defined by Children's Oncology Group (COG) risk classification, including patients initially classified as low or intermediate risk at diagnosis with subsequent reclassification as high-risk disease
  • With relapsed or refractory disease, including at least one of the following:; Recurrent disease at any time after completion of frontline therapy; Progressive disease at any time following standard induction therapy; Primary resistant or refractory disease defined by failure to achieve a complete response by International Neuroblastoma Response Criteria (INRC) after at least four cycles of standard, multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol
  • Patients must have evaluable disease documented within four weeks of study enrollment. Evaluable disease must include at least one of the following:; Measurable tumor (>10 mm in at least one dimension) on MRI or CT scan that is either MIBG, FDG or 68Ga-DOTATATE avid; One or more MIBG, FDG, or 68Ga-DOTATATE avid bone lesion; Microscopic marrow metastasis based on routine morphology and/or immunohistochemistry in at least one sample from bilateral aspirates and biopsies at the time of study enrollment
  • With performance level of >50% on Lansky (<16 years) or Karnofsky (>16 years) scales. Patients who are wheelchair bound due to paralysis will be considered ambulatory when assessing their performance score
  • Adequate baseline cardiac and pulmonary function including a left ventricular ejection fraction (LVEF) >50% by echocardiogram and pulse oximetry >92% on room air documented within four weeks of study enrollment
  • Adequate baseline hematologic function: peripheral absolute neutrophil count (ANC) ≥500/µL, with no receipt of long-acting myeloid growth factors within 14 days or short-acting myeloid growth factors within 7 days of study entry, and a platelet count ≥50,000/µL, with patients required to be transfusion independent for at least 7 days, unless cytopenias are related to marrow metastasis as defined above
  • With available haploidentical related donors

Who cannot take part

  • Infectious disease: Active, uncontrolled infection or received a live vaccine within 30 days prior to study enrollment
  • Concomitant medications: receiving >0.5 mg/kg prednisone equivalent daily
  • Receipt of any concomitant investigational treatments within 30 days at the time of the infusion of the IP. These investigational treatments include drugs, biologics, or devices that are still under investigation in clinical trials or research settings. The use of such agents may confound study results or pose additional safety risks
  • Pulmonary function: Active interstitial lung disease (ILD)/pneumonitis or history of ILD/pneumonitis requiring systemic corticosteroid treatment
  • Known allergy or hypersensitivity reaction to IL-2 injections
  • Cardiac function: LVEF <50% by echocardiogram, serious uncontrolled cardiac arrhythmias, or history of myocarditis or congestive heart failure (New York Heart Association Functional Classification III or IV)
  • Renal function: Glomerular Function Rate (GFR) <50 mL/min/1.73 m2 as measured by cystatin C or NM GFR
  • Hepatic function: Total bilirubin >5 mg/dL, AST and ALT >10 times the upper limit of normal
  • Pregnant or breastfeeding women

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 39 years old?

Where in United States

  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Caitlin CottrellTaking people

About the trial

What the trial wants to find out

The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be generated from donor cells and infused safely into patients with relapsed or refractory neuroblastoma during dinutuximab-based therapy.

The group in the trial

  • Cytokine-Induced Memory-Like Natural Killer (CIML-NK) CellsTreatment being tested

    The investigational cell product is a cytokine-induced memory-like natural killer cell preparation, derived from the recipient's haploidentical donor's apheresis product.

    Treatment: CIML-NK Cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
Plain-language title
Donor-derived natural killer cells for neuroblastoma that has returned or not respondedGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07635056, who can take part
Record updated
24 August 2026